Entecavir Cuts Hep B Reactivation in Diffuse Large B-Cell Lymphoma
Entecavir more efficacious than lamivudine for patients receiving R-CHOP treatment
TUESDAY, Dec. 16, 2014 (HealthDay News) -- Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy treatment. These findings have been published in the Dec. 17 issue of the Journal of the American Medical Association.
He Huang, M.D., from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy treatment. Patients were seropositive for the hepatitis B surface antigen and had normal liver function. They were randomized to daily 0.5 mg entecavir (61 patients) or 100 mg lamivudine (60 patients) beginning one week before R-CHOP initiation.
The researchers found that the incidence of HBV-related hepatitis was significantly lower in the entecavir group than in the lamivudine group (0 versus 13.3 percent; P = 0.003). The incidence of HBV reactivation was also significantly lower in the entecavir group (6.6 versus 30.0 percent; P = 0.001), as was chemotherapy disruption (1.6 versus 18.3 percent; P = 0.002).
"If replicated, these findings support the use of entecavir in these patients," the authors write.